drugset / Trial / NCT06394804
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.
Timeline
- Start
- 2024-04-29
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 2.4 mg | Oral |
| Subject | Avutometinib | Small molecule | 3.2 mg | Oral |
| Subject | Defactinib | Small molecule | 200 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |